{"schema_version":"secwatch.filing_event.v1","accession":"0001649094-25-000096","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.559787+00:00","generated_at":"2026-05-17T19:32:01.919501+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vaxcyte Q2 net loss $166.6M, cash $2.83B; VAX-31 Phase 3 on track for Q4 start","bullets":["Net loss $166.6M for Q2 2025 vs $128.7M a year ago; R&D expenses $194.2M, up from $131.5M.","Cash, cash equivalents and investments $2.83B as of June 30, 2025; cash runway extended to mid-2028.","VAX-31 adult pivotal non-inferiority study to begin Q4 2025 with topline data expected in 2026.","VAX-31 infant Phase 2 modified: new optimized dose arm added, low dose arm discontinued; data by H1 2027.","Early pipeline streamlined: paused VAX-A1 and VAX-GI, discontinued VAX-PG due to insufficient efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0001649094-25-000096","json":"https://secwatch.observer/filing/0001649094-25-000096.json","markdown":"https://secwatch.observer/filing/0001649094-25-000096.md","text":"https://secwatch.observer/filing/0001649094-25-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/0001649094-25-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:32:01.919501+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}